Skip to main navigation
Our Company
About Us
Executive Team
Board of Directors
Scientific and Clinical Advisors
Partners
Our Science
Overview
CD6-ALCAM Pathway
Itolizumab
Publications & Presentations
Pipeline
Overview
Pipeline Graphic
Clinical Trials
Patients
Therapeutic Areas
Graft-Versus-Host Disease
Uncontrolled Moderate to Severe Asthma
SLE / Lupus Nephritis
Clinical Trials
The EQUATE study
The EQUIP study
The EQUALISE study
Investors
Investor Overview
Stock Quote & Chart
Historical Price Lookup
News
Events & Presentations
Analyst Coverage
SEC Filings
Governance Highlights
Committee Composition
Investor FAQ
Alerts & Contacts
Careers
Contact Us
Our Company
About Us
Executive Team
Board of Directors
Scientific and Clinical Advisors
Partners
Our Science
Overview
CD6-ALCAM Pathway
Itolizumab
Publications & Presentations
Pipeline
Overview
Pipeline Graphic
Clinical Trials
Patients
Therapeutic Areas
Graft-Versus-Host Disease
Uncontrolled Moderate to Severe Asthma
SLE / Lupus Nephritis
Clinical Trials
The EQUATE study
The EQUIP study
The EQUALISE study
Investors
Investor Overview
Stock Quote & Chart
Historical Price Lookup
News
Events & Presentations
Analyst Coverage
SEC Filings
Governance Highlights
Committee Composition
Investor FAQ
Alerts & Contacts
Careers
Contact Us
Event Details
Investor Relations
Investor Overview
Stock Quote & Chart
Historical Price Lookup
News
Events & Presentations
Analyst Coverage
SEC Filings
Governance Highlights
Committee Composition
Investor FAQ
Alerts & Contacts
SVB Leerink 10th Annual Global Healthcare Conference
Feb 25, 2021 at 11:20 AM EST
Listen to webcast
Scroll to top
